Meprelon (Methylprednisolone Sodium Succinate)

Meprelon, a glucocorticoid, is used in clinical settings to manage disorders driven by inflammation or immune activation.

• Acute severe asthma: rapid reduction of airway inflammation and bronchospasm, improving breathing.
• Anaphylaxis and severe allergic reactions: swift suppression of systemic allergic response and edema.
• Rheumatoid arthritis flare: decreases joint inflammation and pain during acute exacerbations.
• Multiple sclerosis relapse: mitigates central nervous system inflammation to shorten relapse duration.

• Meprelon delivers methylprednisolone sodium succinate, which diffuses into cells and binds intracellular glucocorticoid receptors. The receptor complex translocates to the nucleus and binds glucocorticoid response elements, modulating transcription of anti‑inflammatory genes while repressing pro‑inflammatory cytokine production. This results in decreased leukocyte migration, reduced capillary permeability, and overall suppression of immune activation.

Meprelon may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.
• Fluid retention: peripheral edema and weight gain.
• Mood changes: anxiety, insomnia, or euphoria.
• Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.

Serious or Rare Side Effects

• Severe infection: increased susceptibility to bacterial, viral, or fungal infections.
• Adrenal insufficiency: suppression of endogenous cortisol production leading to crisis on abrupt withdrawal.
• Osteonecrosis: bone tissue death, particularly in weight‑bearing joints.

When prescribing Meprelon, clinicians should consider several precautionary measures to minimize risk.

• Assess infection risk: evaluate for active or latent infections before initiating therapy.
• Monitor glucose: check blood sugar levels in diabetic or pre‑diabetic patients.
• Screen for osteoporosis: consider bone density assessment in long‑term users.
• Tapering requirement: avoid abrupt discontinuation to prevent adrenal crisis.
• Pregnancy and lactation: use only if benefits outweigh potential risks; discuss with obstetrician.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meprelon can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase systemic glucocorticoid exposure, raising toxicity risk.
• Live vaccines: concurrent use can diminish vaccine efficacy and increase infection risk.
• Anticoagulants (e.g., warfarin): glucocorticoids may enhance anticoagulant effect, requiring close INR monitoring.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined use raises gastrointestinal ulcer risk.
• Diuretics (e.g., furosemide): may potentiate electrolyte disturbances such as hypokalemia.